Compare · COLL vs JNJ
COLL vs JNJ
Side-by-side comparison of Collegium Pharmaceutical Inc. (COLL) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COLL and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $537.39B, about 533.4x COLL ($1.01B).
- COLL has been more active in the news (20 items in the past 4 weeks vs 12 for JNJ).
- JNJ has more recent analyst coverage (25 ratings vs 20 for COLL).
- Company
- Collegium Pharmaceutical Inc.
- Johnson & Johnson
- Price
- $31.06+1.82%
- $223.61+0.31%
- Market cap
- $1.01B
- $537.39B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2015
- News (4w)
- 20
- 12
- Recent ratings
- 20
- 25
Collegium Pharmaceutical Inc.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest COLL
- SEC Form S-8 filed by Collegium Pharmaceutical Inc.
- SEC Form S-8 filed by Collegium Pharmaceutical Inc.
- Collegium to Participate in 2026 Jefferies Global Healthcare Conference
- Director Freund John Gordon sold $681 worth of shares (20 units at $34.05), decreasing direct ownership by 0.02% to 83,952 units (SEC Form 4)
- Director Bohlin Garen G was granted 8,741 shares, increasing direct ownership by 14% to 71,000 units (SEC Form 4)
- Director Freund John Gordon was granted 8,741 shares, exercised 8,700 shares at a strike of $16.49 and sold $142,547 worth of shares (4,127 units at $34.54), increasing direct ownership by 19% to 83,972 units (SEC Form 4)
- Director Paya Carlos V was granted 8,741 shares, increasing direct ownership by 45% to 28,323 units (SEC Form 4)
- Director Lurker Nancy was granted 8,741 shares, increasing direct ownership by 49% to 26,758 units (SEC Form 4)
- Director Balice-Gordon Rita J. was granted 8,741 shares, increasing direct ownership by 17% to 61,370 units (SEC Form 4)
- Director Glancy Donovan Michael was granted 17,482 shares (SEC Form 4)
Latest JNJ
- Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
- Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
- RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
- New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
- FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
- Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
- SEC Form SD filed by Johnson & Johnson
- SEC Form 13F-HR filed by Johnson & Johnson
- CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research
- Johnson & Johnson upgraded by Leerink Partners with a new price target